1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a healthcare technology and
Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a
Cross-border initiative expands Lōkahi's university network, increases capacity for additional revenue generating strategic partnerships, and brings together U.S. and German students to identify and evaluate
Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow
Lōkahi Therapeutics™, a
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced the pricing of a "best efforts" public offering of 169,388 shares of common stock at a price of $2.04 per share
Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development
Lōkahi Therapeutics™ Inc.,
Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including
ai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi's therapeutic development platform.
Lōkahi Therapeutics™ Inc., a subsidiary of
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and
1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a healthcare technology and
One year of work focused on one goal: manufacturing clinical material to enable once-weekly dosingLōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it has started its
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed
